Results 181 to 190 of about 1,616,230 (293)

Data on the profile of organic contaminants in the L'Albufera Natural Park (2019-2020). Target and non-target screening. [PDF]

Data Brief
Soriano Y, Doñate E, Asins S, Andreu V, Picó Y.   +4 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Identification of Potentially Toxic Transformation Products Produced in Polycyclic Aromatic Hydrocarbon Bioremediation Using Suspect and Non-Target Screening Approaches. [PDF]

Environ Sci Technol
Huizenga JM, Semprini L, Garcia-Jaramillo M.   +2 more
europepmc   +1 more source

Non-target screening - identifikation af nye kemikalier i indemiljøet [PDF]

, 2022
Fauser, Patrik, Zhu, Linyan, Sanderson, Hans, Mikkelsen, Lone, Vorkamp, Katrin   +4 more
openaire  

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Presence of Micropollutants and Transformation Products During Subsurface Irrigation with Treated Wastewater Assessed by Non-Target Screening Analysis. [PDF]

ACS ES T Water
Ore A, Helmus R, Narain-Ford DM, Bartholomeus RP, Sutton NB, van Wezel A.   +5 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Genomic, Transcriptomic and Suspect/Non-Target Screening Analyses Reveal the Role of CYP450s in the Degradation of Imazalil and Delineate Its Transformation Pathway by Cladosporium herbarum. [PDF]

Microb Biotechnol
Papazlatani CV, Vasileiadis S, Panagopoulou EI, Damalas DE, Karas PA, Gerovasileiou E, Thomaidis NS, Karpouzas DG.   +7 more
europepmc   +1 more source

Preliminary versions of suspect screening and non target screening (NTS) methods analysis

Produced as a result of T1.1, including ST1.1.1 and ST1.1.2. Description: A report including a draft of the standard operating protocol (SOP) for LC-MS based suspect screening and NTS analysis. The SOP will include a flow diagram and description of each of the steps The development of this deliverable will include collection of water samples in the 3 ...
openaire   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source